Compare LAB & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAB | LCTX |
|---|---|---|
| Founded | 1999 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 326.2M | 301.7M |
| IPO Year | 2008 | 1996 |
| Metric | LAB | LCTX |
|---|---|---|
| Price | $0.69 | $1.08 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $1.35 | ★ $6.25 |
| AVG Volume (30 Days) | ★ 1.5M | 804.3K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.54 | N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $101,937,000.00 | $14,556,000.00 |
| Revenue This Year | N/A | $109.40 |
| Revenue Next Year | $2.63 | N/A |
| P/E Ratio | $2.58 | ★ N/A |
| Revenue Growth | N/A | ★ 53.24 |
| 52 Week Low | $0.63 | $1.00 |
| 52 Week High | $1.72 | $2.09 |
| Indicator | LAB | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.83 | 46.46 |
| Support Level | $0.63 | $1.02 |
| Resistance Level | $1.02 | $1.18 |
| Average True Range (ATR) | 0.04 | 0.05 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 47.15 | 34.48 |
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.